Entropy Technologies LP Purchases Shares of 12,346 Guardant Health, Inc. (NASDAQ:GH)

Entropy Technologies LP purchased a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 12,346 shares of the company’s stock, valued at approximately $377,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. JNBA Financial Advisors acquired a new stake in Guardant Health in the third quarter valued at $26,000. R Squared Ltd acquired a new stake in Guardant Health in the fourth quarter valued at $26,000. Ashton Thomas Securities LLC acquired a new stake in Guardant Health in the third quarter valued at $34,000. Nisa Investment Advisors LLC raised its holdings in Guardant Health by 168.1% in the third quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company’s stock valued at $79,000 after acquiring an additional 2,153 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Guardant Health by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock valued at $102,000 after acquiring an additional 796 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the transaction, the director now directly owns 2,676 shares of the company’s stock, valued at approximately $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 2,652 shares of company stock valued at $93,192 over the last ninety days. 5.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on GH shares. JPMorgan Chase & Co. upped their price target on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Barclays began coverage on shares of Guardant Health in a research report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target for the company. Leerink Partners lowered their price target on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Sanford C. Bernstein decreased their target price on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. Finally, Guggenheim reiterated a “buy” rating on shares of Guardant Health in a research report on Wednesday, January 22nd. Sixteen investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $42.63.

Guardant Health Price Performance

Shares of GH stock opened at $45.38 on Thursday. The stock has a market cap of $5.61 billion, a P/E ratio of -10.70 and a beta of 1.32. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $50.89. The stock has a fifty day moving average price of $38.60 and a 200 day moving average price of $30.91.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.